Display Settings:

Format

Send to:

Choose Destination
    Urol Oncol. 2005 Nov-Dec;23(6):383-5.

    Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.

    Source

    Department of Urology, V.M. Medical College & Safdarjang Hospital, New Delhi, India. nayankm@yahoo.co.in

    Abstract

    OBJECTIVE:

    Because of its long latency, slow growing nature, and high prevalence, prostate cancer is the best model for chemoprevention. High-grade prostate intraepithelial neoplasia (HGPIN) is a precursor of prostate cancer. Chemoprevention with lycopene has shown definite results in prostate cancer. We undertook a study to use lycopene as a chemopreventive agent in the treatment of HGPIN for preventing prostate cancer from developing in this vulnerable group of patients.

    MATERIALS AND METHODS:

    A total of 40 patients with HGPIN were randomized into 2 groups: one received 4 mg lycopene twice a day for one year, and the other was periodically followed up. Total follow-up was one year.

    RESULTS:

    Our results show that lycopene can delay or prevent HGPIN from developing into occult prostate cancer, and there exists an inverse relationship between lycopene and prostate-specific antigen. Being a vegetable carotenoid, lycopene is a safe drug to be used for a longer period without any adverse reaction.

    CONCLUSION:

    Lycopene is an effective chemopreventive agent in the treatment of HGPIN, with no toxicity and good patient tolerance.

    PMID:
    16301113
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk